NEW YORK (GenomeWeb) — Bio-Rad reported after the close of the market on Tuesday a 2 percent increase in second quarter revenues despite essentially flat sales for its Life Science segment.

For the quarter ended June 30, the Hercules, Calif.-based firm reported revenues of $536.8 million compared to $525.3 million in Q2 2013 and falling short of the consensus analyst estimate of $537.6 million.

On a currency-neutral basis, quarterly revenues increased 1 percent year over year.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

In Science this week: swapping yeast genes with human orthologs to study conservation of function, and more.

Hong Kong is using DNA phenotyping to shame litterers.

A study appearing in Cell suggests some metastatic castration-resistant prostate cancer patients could benefit from PARP inhibitor therapy.

NIH's Francis Collins writes that scientific advances are poised to help populations all over the world, but more scientists are needed to keep the momentum.